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Abstract: Venous thromboembolism (VTE), encompassing deep vein thrombosis and 
 pulmonary embolism, represents a major cause of morbidity and mortality in patients with 
cancer. Low molecular weight heparins are the preferred option for anticoagulation in cancer 
patients according to current clinical practice guidelines. Fondaparinux may also have a place 
in prevention of VTE in hospitalized cancer patients with additional risk factors and for initial 
treatment of VTE. Although low molecular weight heparins and fondaparinux are effective 
and safe, they require daily subcutaneous administration, which may be problematic for 
many patients, particularly if long-term treatment is needed. Studying anticoagulant therapy 
in oncology patients is challenging because this patient group has an increased risk of VTE 
and bleeding during anticoagulant therapy compared with the population without cancer. Risk 
factors for increased VTE and bleeding risk in these patients include concomitant treatments 
(surgery, chemotherapy, placement of central venous catheters, radiotherapy, hormonal therapy, 
angiogenesis inhibitors, antiplatelet drugs), supportive therapies (ie, steroids, blood transfusion, 
white blood cell growth factors, and erythropoiesis-stimulating agents), and tumor-related fac-
tors (local vessel damage and invasion, abnormalities in platelet function, and number). New 
anticoagulants in development for prophylaxis and treatment of VTE include parenteral com-
pounds for once-daily administration (ie, semuloparin) or once-weekly dosing (ie, idraparinux 
and idrabiotaparinux), as well as orally active compounds (ie, dabigatran, rivaroxaban, apixa-
ban, edoxaban, betrixaban). In the present review, we discuss the pharmacology of the new 
anticoagulants, the results of clinical trials testing these new compounds in VTE, with special 
emphasis on studies that included cancer patients, and their potential advantages and drawbacks 
compared with existing therapies.
Keywords: anticoagulants, venous thromboembolism, cancer, dabigatran, apixaban, 
rivaroxaban
Introduction
Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary 
embolism, is the third leading cause of mortality due to circulatory diseases, second 
only to myocardial infarction and stroke.1 On the other hand, cancer is responsible 
for 25% of all deaths in developed countries,2 only exceeded by circulatory diseases. 
The two-way association between thrombosis and cancer has been well established 
since the first description by Jean Baptiste Bouillaud in 1823,3 developed further by 
Armand Trousseau in 1865.4 Patients with cancer have at least a six-fold increased 
risk of VTE compared with those without cancer,5 and the diagnosis of VTE in can-
cer patients is associated with a 2–4-fold decreased survival during the first year.6 
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Conversely, VTE can be the first sign of a cancer. Patients in 
the general population who develop symptomatic VTE have 
a 2–4-fold increased risk of cancer diagnosis in the first year 
after the VTE event.7,8
Studying anticoagulant therapy in oncology patients is 
challenging for several reasons. First, there are differences 
in VTE risk across the cancer population. Certain cancers 
(metastatic cancer, pancreas, ovary, lung, colon, stomach, 
prostate, and kidney adenocarcinomas, as well as malignant 
brain tumors and hematological malignancies) are strongly 
associated with the development of VTE.9 Therapies for 
 cancer, such as surgery, chemotherapy, and placement of cen-
tral venous catheters, radiotherapy, hormonal manipulation 
(eg, tamoxifen), angiogenesis inhibitors (eg, bevacizumab, 
thalidomide, lenalidomide), and supportive therapies (ie, 
 steroids, blood transfusion, white blood cell growth factors, 
and erythropoiesis-stimulating agents) may also increase the 
risk of VTE.10,11 Further, cancer patients have an increased 
risk of excessive bleeding during anticoagulant therapy 
compared with the population without cancer,12 which 
may have several causes, including surgery, liver failure, 
chemotherapy, radiotherapy, use of antiplatelet drugs, or 
tumor-related factors (local vessel damage and invasion, 
abnormalities in platelet functioning and number).10
Low molecular weight heparins (LMWH) are preferred 
over other anticoagulants (ie, fondaparinux, unfractionated 
heparin) or vitamin K antagonists (ie, warfarin, acenocouma-
rol) in cancer patients, according to clinical practice guidelines 
published by the American College of Chest Physicians,13–15 
the GFTC initiative,16 the European Society of Medical Oncol-
ogy,17 the American Society of Clinical Oncology,18 and the 
National Comprehensive Cancer  Network.19 Fondaparinux 
may be an alternative to LMWH for prevention of VTE in hos-
pitalized cancer patients with at least one additional risk factor 
for VTE, and for initial treatment of VTE, but it is not gener-
ally recommended for prevention of VTE after cancer surgery 
or for long-term or extended treatment of VTE (Table 1).13–15 
Unfractionated heparin may provide an alternative to LMWH 
and fondaparinux in patients with renal impairment.15 The 
preference for LMWH over vitamin K antagonists in cancer 
patients is based on several considerations: LMWH is more 
effective than vitamin K antagonists and is equally safe 
in the long-term treatment of VTE;15 LMWH is easier to 
handle than vitamin K antagonists in the event of invasive 
procedures, which are frequent in cancer patients and may 
require rapid reversal with rapid reintroduction of antico-
agulation; there may be an unpredictable response to vitamin 
K antagonist therapy in cancer patients because of the high 
risk of  drug-drug interactions with cancer chemotherapy, as 
well as the frequent presence of vomiting associated with 
chemotherapy and subsequent poor oral absorption;15 vitamin 
K  antagonists have a slow onset of action, which implies a 
need for overlap with a parenteral anticoagulant in the event of 
acute VTE; and the narrow therapeutic window and variability 
in response to vitamin K antagonists implies that frequent 
anticoagulant monitoring [using the prothrombin time and 
its reporting as the international normalized ratio (INR)] is 
necessary to avoid subtherapeutic anticoagulation associated 
with an increased risk of thrombosis or excessive anticoagu-
lation that increases the risk of bleeding. Such monitoring 
is inconvenient for patients and medical staff, and costly for 
health care payers.
Despite LMWH and fondaparinux being effective and 
safe, they still require daily parenteral subcutaneous admin-
istration, which may be problematic for many patients, 
particularly if long-term treatment is needed. In addition, 
they are cleared mainly through the kidneys, and their use in 
patients with severe renal insufficiency may be problematic. 
LMWH is only partially neutralized by protamine, and no 
specific antidote is available for fondaparinux.
New anticoagulants include parenteral compounds for 
once-daily administration (ie, semuloparin) or once-weekly 
dosing (ie, idrabiotaparinux), as well as orally active com-
pounds (ie, dabigatran, rivaroxaban, apixaban, edoxaban, 
betrixaban).
In this review, we discuss the pharmacology of the 
new anticoagulants and the results of clinical trials test-
ing these compounds in VTE, with special emphasis on 
studies that included cancer patients. With this objec-
tive, we searched Medline (up to December 1, 2012) and 
clinical trial registries (ie, clinicaltrials.gov) using the terms 
 “cancer”,  “semuloparin”, “idraparinux”, “idrabiotaparinux”, 
 “rivaroxaban”, “apixaban”, “edoxaban”, “betrixaban”, 
and “dabigatran”. We also searched regulatory agency web-
sites (US Food and Drug Administration, European Medi-
cines Agency) and relevant conference proceedings related 
to anticoagulation and cancer, ie, International Conference of 
Thrombosis and Hemostasis Issues in Cancer, International 
Society of Thrombosis and Hemostasis, American Society 
of Clinical Oncology, American Society of Hematology, and 
Mediterranean League Against Thromboembolic Diseases.
Mechanism of action of new 
anticoagulants
The new anticoagulants that are currently approved or 
in clinical development for indications related to the 
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 prophylaxis and treatment of VTE target activated Factor X 
(FXa) or activated factor II (FIIa, thrombin, Figure 1).
FXa controls generation of thrombin, and inhibition of 
one molecule of FXa may result in inhibition of generation 
of 1000 molecules of FIIa.20 Thrombin plays a central role 
in hemostasis by regulating blood coagulation and inducing 
platelet aggregation.21 It is formed from its precursor, pro-
thrombin, and converts fibrinogen to fibrin in the final step 
of the clotting cascade (Figure 1). Thrombin also promotes 
numerous cellular effects, ie, it plays a role in inflammation 
and cellular proliferation, and displays mitogen activity in 
smooth muscle cells and endothelial cells, predominantly 
by activation of angiogenesis.22 Preclinical data suggest 
that thrombin inhibition may result in inhibition of both 
tumor growth and metastases.23,24 Therefore, use of anti-
coagulation in cancer patients might be beneficial not only 
in preventing thrombotic events, but also as an adjuvant 
anticancer therapy.
FXa inhibitors block generation of thrombin, while 
thrombin inhibitors block the activity of thrombin. FXa 
inhibitors include parenteral drugs that indirectly inhibit FXa 
by binding to antithrombin (ie, semuloparin, idraparinux, 
idrabiotaparinux) and orally active agents that directly inhibit 
FXa (rivaroxaban, apixaban, edoxaban, betrixaban). Oral 
direct thrombin inhibitors include the prodrug dabigatran 
etexilate, AZD0837, and S35972.25
Development of several promising new oral direct FXa 
inhibitors for VTE has recently been halted, including for 
darexaban (YM150, Astellas Pharma Inc, Tokyo, Japan),26 
letaxaban (TAK-442, Takeda Pharmaceutical Company 
Limited, Tokyo, Japan), eribaxaban (PD0348292, Pfizer 
Inc, New York, NY, USA),27 AZD0837, and S35972. 
These new anticoagulants will not be discussed further in 
the review.
Among the new anticoagulants, dabigatran etexilate 
(Pradaxa®, Boehringer Ingelheim, Ingelheim, Germany), 
rivaroxaban (Xarelto®, Bayer HealthCare, Leverkusen, 
 Germany), and apixaban (Eliquis®, Bristol-Myers Squibb, 
New York, NY, USA) are currently approved in the 
 European Union, the US, and other regions in several indica-
tions related to anticoagulation, while edoxaban (Lixiana®, 
Daiichi-Sankyo Inc, Parsippany, NJ, USA) is approved 
in Japan for thromboprophylaxis after major orthopedic 
surgery (Table 2).
Novel parenteral indirect FXa 
inhibitors
Semuloparin
Semuloparin sodium (AVE5026, Mulsevo®, Sanofi-Aventis, 
Bridgewater, NJ, USA) is a new ultralow molecular weight 
heparin obtained by phosphazene-promoted depolymerization 
of heparin from porcine intestinal mucosa, leading to a pool 
of polysaccharide chains with an individual molecular weight 
distribution (mean molecular weight 2000–3000 Da).28–30 It 
has predominantly anti-FXa activity (ratio anti-FXa/anti-FIIa 
approximately 80) and a half-life of 16–20 hours, which 
allows once-daily subcutaneous administration. Its excre-
tion is mainly renal.28 At equipotent doses, semuloparin did 
not affect bleeding parameters, whereas enoxaparin showed 
increased risk of hemorrhage in rats, rabbits, and dogs.29 The 
anticoagulant effects of semuloparin are not neutralized by 
protamine.31 Preliminary in vitro evaluation of semuloparin 
indicates a low risk for immune-mediated heparin-induced 
thrombocytopenia.29
Semuloparin was at least as effective as enoxaparin 
in preventing VTE after total knee arthroplasty (SAVE-
KNEE study)32 and total hip replacement (SAVE-HIP1 
and SAVE-HIP2 studies),32 and was more effective than 
placebo for extended VTE prophylaxis after hip fracture 
surgery.33 However, no superior efficacy to enoxaparin 
was shown for major VTE (after excluding asymptomatic 
distal deep vein thrombosis) in a pooled analysis,34 and 
the risk of clinically relevant bleeding with semuloparin 
varied across trials.
Two additional studies were conducted in cancer 
patients undergoing chemotherapy (SAVE-ONCO)35–37 
and in patients undergoing major abdominal surgery, the 
majority of them because of cancer (SAVE-ABDO).36–38 
Intrinsic pathway
amplification
IXa
VIIIa VIIa FT
Va
AT
Rivaroxaban
Apixaban
Edoxaban
Semuloparin
Idraparinux
Idrabiotaparinux
Betrixaban
Dabigatran
XIa
Xa
IIa
XIIa
Extrinsic pathway
Initiation
Propagation
Oral
Fibrin
thrombus
Thrombus
Formation
(Thrombin)
Parenteral
Fibrinogen
Figure 1 New anticoagulants and their targets in the coagulation cascade.*
Note: *Continuous line indicates activation; dashed line indicates inhibition.
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The results of these studies are shown in Table 3 and dis-
cussed below.
VTE prophylaxis in medical patients 
undergoing chemotherapy
SAVE-ONCO35–37 was a double-blind multicenter trial evalu-
ating the efficacy and safety of semuloparin for prevention of 
VTE in patients receiving chemotherapy for cancer. A total 
of 1150 patients with metastatic or locally advanced solid 
tumors and embarking on a course of chemotherapy were 
randomly assigned to receive subcutaneous semuloparin 
20 mg once daily or placebo for a median of 3.5 months. 
The most common primary malignancies were lung (37%) 
or colorectal (29%) cancer, with a smaller proportion of 
patients having cancer of the stomach (13%), ovary (12%), 
pancreas (8%), or bladder (2%). Most patients (69%) had 
metastatic disease at study entry, and more than 90% of 
patients in this trial had Eastern Cooperative Oncology 
Group performance status of 0 or 1.36,37 The most common 
chemotherapeutic agents included platinum compounds and 
pyrimidine analogs. In total, 42% of patients had at least one 
additional VTE risk factor, and 2.3% of patients had at least 
three VTE risk factors.
The primary efficacy outcome (composite of any symp-
tomatic deep vein thrombosis, any nonfatal pulmonary 
embolism, and death related to VTE) occurred in 1.2% 
of patients (20/1608) receiving semuloparin, as compared 
with 3.4% (55/1604) receiving placebo (absolute risk 
difference −2.2%; hazard ratio [HR] 0.36; 95% confidence 
interval [CI] 0.21–0.60; P , 0.001). VTE-related death 
occurred in only 0.4% and 0.6% of patients receiving semu-
loparin and  placebo, respectively. In relative terms, efficacy 
was consistent among subgroups defined according to the 
origin and stage of cancer and the baseline risk of VTE. 
However, the subgroup analyses also suggest that there may 
be a sizable variation in the absolute benefit depending on 
tumor type and baseline VTE risk between patients, with 
pancreatic subtype and a VTE risk score $ 3 being associated 
with greater absolute benefit (absolute risk reduction 8.5% 
and 3.9% versus placebo, respectively).36,37
The incidence of clinically relevant bleeding was 
2.8% and 2.0% in the semuloparin and placebo groups, 
respectively (absolute risk difference +0.8%; HR 1.40; 
95% CI 0.89–2.21). However, there were more patients 
with  treatment-emergent bleeding events overall in the 
semuloparin group compared with the placebo group (20% 
versus 16%, respectively), including serious cases (1.9% 
versus 1.5%).36 Rates of major bleeding were similar in 
both treatment groups (1.2% versus 1.1%). Fatal bleeding 
occurred in two and four patients in the semuloparin and 
placebo groups, respectively. However, major bleeding into 
a critical area or organ, as included in a US Food and Drug 
Administration analysis, was observed in seven patients in 
the semuloparin group and no patients in the placebo group. 
These cases included two pericardial, one intraocular (result-
ing in retinal detachment), one splenic, and three intracranial 
bleeds, of which one case was fatal.37 Rates of all deaths 
during the overall study period (43.4% versus 44.5%)35 and 
on-treatment deaths (15.7% versus 15.9%)37 were similar in 
the two study groups.
In conclusion, semuloparin reduced the incidence of VTE 
in patients receiving chemotherapy for cancer, with sizable 
variation in the absolute benefit depending on tumor type 
and baseline VTE risk. Although there was no significant 
increase in overall major bleeding, there was a trend towards 
a higher risk of bleeding into a critical area or organ with 
semuloparin in comparison with placebo. No trend towards 
a survival benefit was noted.
VTE prophylaxis in major abdominal 
surgery
SAVE-ABDO36–38 was a randomized, active-controlled trial 
for the prevention of VTE in patients undergoing major 
abdominal surgery for indications other than disease of the 
liver, uterus, or prostate. Patients younger than 60 years of 
age had to have one of the following additional risk factors: 
cancer surgery, history of VTE, body mass index $ 30 kg/m2, 
chronic heart failure, chronic respiratory failure, or inflamma-
tory bowel disease. A total of 4413 patients were randomized 
1:1 to receive either semuloparin 20 mg subcutaneous once 
daily started postoperatively or enoxaparin 40 mg subcu-
taneous once daily started preoperatively for a duration of 
7–10 days after surgery, of which 3030 patients were assess-
able for efficacy. This trial failed to meet its primary efficacy 
endpoint of any VTE or all-cause death in a noninferiority 
comparison of semuloparin versus enoxaparin (6.3% versus 
5.5%; odds ratio [OR] 1.16; 95% CI 0.87–1.54; noninferior-
ity margin 1.25).36,37 Rates of major VTE or all-cause deaths 
(secondary endpoint) were similar in the semuloparin and 
enoxaparin groups (2.2% versus 2.3%; OR 0.95; 95% CI 
0.61–1.49).
Eighty-one percent (n = 2451) of the primary efficacy pop-
ulation was composed of patients with cancer and undergoing 
oncological surgery. An exploratory analysis by the US Food 
and Drug Administration in the subgroup of patients with 
cancer showed a numerically higher proportion of subjects 
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Table 2 Characteristics of old and new anticoagulants*
Parenteral anticoagulants Oral anticoagulants
Agent Heparin sodium LMwH† Semuloparin Fondaparinux Idrabiotaparinux Vitamin K antagonists‡ Dabigatran etexilate Rivaroxaban Apixaban Edoxaban Betrixaban
Source Pig intestinal mucosa Pig intestinal mucosa Pig intestinal mucosa Synthetic Synthetic Synthetic Synthetic Synthetic Synthetic Synthetic Synthetic
Molecular  
weight (Da)
12,000–15,000 3600–6500 2000–3000 1728 1727 (idraparinux) + 
244 (biotin)
About 1000 628 436 460 548 452
Target FXa = FIIa 
(1 to 1 ratio)
FXa . FIIa 
(2 to 8:1 ratio)
FXa . FIIa  
(80:1 ratio)
FXa only FXa only FII, VII, IX, X, protein C, S Thrombin FXa FXa FXa FXa
Type of inhibition Indirect (bind to AT) Indirect (bind to AT) Indirect (bind to AT) Indirect (bind to AT) Indirect (bind to AT) Indirect§ Direct Direct Direct Direct Direct
Bioavailability (%) 100 (IV) 90–98 (SC) 98% (SC) About 100 (SC) About 100 (SC) .60 6.5 80–100 50 50% 34%
Tmax Few minutes 2–3 hours 2–3 hours 30–60 minutes 4 hours 1–3 hours 0.5–2 hours 2–4 hours 3–4 hours 1.5 hours 2.5 hours
Drug interactions ¶ ¶ ¶ ¶ ¶ Dietary vitamin K, multiple  
drugs and foods
P-gp inh/ind,  
proton pump inh¶
Potent P-gp and  
CYP3A4 inh/ind¶
Potent P-gp and  
CYP3A4 inh/ind¶
Potent P-gp  
inh/ind¶
Potent P-gp inh/
ind¶
Protein binding (%) High Low Low Low Very low About 99 35 92–95 87 40–60 60
Half-life 0.5–1 hour 3–6 hours 16–20 hours 17–21 hours 120 hours 8–11 hours (acenocoumarol);  
36–42 hours (warfarin)
14–17 hours 7–12 hours 12 hours 6–11 hours 19 hours
Metabolism Depolymerization Desulfation,  
depolymerization (,10%)
Not reported Negligible Negligible CYP2C9/19 (acenocoumarol);  
CYP2C9/1A2/3A4 (warfarin)
Glucuronidation  
(,10%)
CYP3A4 . CYP2J2 CYP3A4/5 . CYP21A2,  
SC8, 2C9/19, 2J2
Hydrolysis Hydrolysis .  
demethylation
Renal excretion (%) Medium High High 64–77 (unchanged) High (unchanged) 92 85 (unchanged) 66 27 36–45 6–13
Biliary excretion (%) Medium Low Low Negligible Negligible 8 6 28 25 NA 82–89
Antidote Protamine Protamine (partially) None None Avidin Vitamin K None None None None None
Monitoring test aPTT Not required routinely 
Anti-Xa assay
Not required  
routinely 
Anti-Xa assay
Not required  
routinely 
Anti-Xa assay
Not required routinely 
Anti-Xa assay
INR Not required routinely 
Diluted thrombin time
Not required routinely 
Anti-Xa assay
Not required routinely 
Anti-Xa assay
NA NA
Approval date 1939 (EU, US) 1985 (EU, dalteparin) 
1993 (US, enoxaparin)
Not yet approved 2000 (US) 
2002 (EU)
Not yet approved 1941 
(US, dicumarol) 
1953 (EU, phenprocoumon)
2008 (EU) 
2010 (US)
2008 (EU) 
2011 (US)
2011 (EU) 
2013 (US)
2011 (Japan) Not yet 
approved
Notes: †Ardeparin, bemiparin, certoparin, dalteparin, enoxaparin, nadroparin, parnaparin, reviparin, tinzaparin; ‡dicumarol (no longer available), warfarin, acenocoumarol, 
phenprocoumon; §inhibition of vitamin K epoxide reductase; ¶potential pharmacodynamic interactions with other drugs that alter haemostasis (eg, other anticoagulants, 
fibrinolytics, and antiplatelet drugs).
Abbreviations: ACT, activated coagulation time; aPTT, activated partial thromboplastin time; AT, antithrombin; inh/ind, inhibitors/inducers; CYP, cytochrome P450; 
EU, European Union; INR, international normalized ratio; IV, intravenous; LMwH, low molecular weight heparin; NA, data not available; PD, pharmacodynamics; P-gp, 
P-glycoprotein; PK, pharmacokinetics; SC, subcutaneous; Tmax, time to maximum concentration; US, United States; VKA, vitamin K antagonist.
with VTE events in the semuloparin arm than the enoxaparin 
arm (7.1% versus 5.9%; OR 1.23; 95% CI 0.89–1.69).37 In the 
overall study population, semuloparin was associated with less 
clinically relevant bleeding (2.9% versus 4.5%; OR 0.63; 95% 
CI 0.46–0.87) and less major bleeding (4.1% versus 5.7%; 
OR 0.71; 95% CI 0.54–0.93) than enoxaparin.
Idraparinux sodium
Idraparinux sodium (SR34006, Sanofi-Aventis and Organon 
Pharmaceuticals Inc, Roseland, NJ, USA), investigated in the 
SANORG 34006 trial, is a long-acting synthetic molecule, 
developed based on the native pentasaccharide sequence 
that binds to antithrombin, thus indirectly inhibiting FXa 
activity.39,40 Idraparinux is almost completely absorbed after 
subcutaneous injection and the time to maximum concentra-
tion is about 4 hours after subcutaneous administration. It 
has a half-life of 120 hours in healthy subjects41 and 66 days 
after multiple doses in patients,42 allowing for once-weekly 
administration. It is excreted unchanged via the kidneys. 
Therefore, there is a risk of accumulation in patients with 
renal insufficiency. The anticoagulant effect may persist for 
3–4 months after termination of therapy.43
Acute and long-term treatment  
of deep vein thrombosis
In a randomized, open-label, noninferiority Phase III trial 
in patients with deep vein thrombosis (van Gogh-DVT, 
n = 2904), idraparinux 2.5 mg once weekly was as effective 
as standard therapy (heparin followed by an adjusted-dose 
vitamin K antagonist) administered for 3–6 months.44 The 
incidence of recurrence at day 92 was 2.9% in the idraparinux 
group as compared with 3.0% in the standard therapy group 
(OR 0.98; 95% CI 0.63–1.50), a result that satisfied the 
prespecified noninferiority requirement (upper limit of the 
95% CI for the OR for documented symptomatic recurrent 
VTE , 2). At 6 months, clinically relevant bleeding rates 
were similar (8.3% versus 8.1%). A post hoc analysis of 
the subgroup of patients with cancer (n = 421) showed that 
idraparinux was as effective as a vitamin K antagonist with 
respect to recurrent VTE (idraparinux 2.5% versus standard 
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Table 2 Characteristics of old and new anticoagulants*
Parenteral anticoagulants Oral anticoagulants
Agent Heparin sodium LMwH† Semuloparin Fondaparinux Idrabiotaparinux Vitamin K antagonists‡ Dabigatran etexilate Rivaroxaban Apixaban Edoxaban Betrixaban
Source Pig intestinal mucosa Pig intestinal mucosa Pig intestinal mucosa Synthetic Synthetic Synthetic Synthetic Synthetic Synthetic Synthetic Synthetic
Molecular  
weight (Da)
12,000–15,000 3600–6500 2000–3000 1728 1727 (idraparinux) + 
244 (biotin)
About 1000 628 436 460 548 452
Target FXa = FIIa 
(1 to 1 ratio)
FXa . FIIa 
(2 to 8:1 ratio)
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(80:1 ratio)
FXa only FXa only FII, VII, IX, X, protein C, S Thrombin FXa FXa FXa FXa
Type of inhibition Indirect (bind to AT) Indirect (bind to AT) Indirect (bind to AT) Indirect (bind to AT) Indirect (bind to AT) Indirect§ Direct Direct Direct Direct Direct
Bioavailability (%) 100 (IV) 90–98 (SC) 98% (SC) About 100 (SC) About 100 (SC) .60 6.5 80–100 50 50% 34%
Tmax Few minutes 2–3 hours 2–3 hours 30–60 minutes 4 hours 1–3 hours 0.5–2 hours 2–4 hours 3–4 hours 1.5 hours 2.5 hours
Drug interactions ¶ ¶ ¶ ¶ ¶ Dietary vitamin K, multiple  
drugs and foods
P-gp inh/ind,  
proton pump inh¶
Potent P-gp and  
CYP3A4 inh/ind¶
Potent P-gp and  
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Potent P-gp  
inh/ind¶
Potent P-gp inh/
ind¶
Protein binding (%) High Low Low Low Very low About 99 35 92–95 87 40–60 60
Half-life 0.5–1 hour 3–6 hours 16–20 hours 17–21 hours 120 hours 8–11 hours (acenocoumarol);  
36–42 hours (warfarin)
14–17 hours 7–12 hours 12 hours 6–11 hours 19 hours
Metabolism Depolymerization Desulfation,  
depolymerization (,10%)
Not reported Negligible Negligible CYP2C9/19 (acenocoumarol);  
CYP2C9/1A2/3A4 (warfarin)
Glucuronidation  
(,10%)
CYP3A4 . CYP2J2 CYP3A4/5 . CYP21A2,  
SC8, 2C9/19, 2J2
Hydrolysis Hydrolysis .  
demethylation
Renal excretion (%) Medium High High 64–77 (unchanged) High (unchanged) 92 85 (unchanged) 66 27 36–45 6–13
Biliary excretion (%) Medium Low Low Negligible Negligible 8 6 28 25 NA 82–89
Antidote Protamine Protamine (partially) None None Avidin Vitamin K None None None None None
Monitoring test aPTT Not required routinely 
Anti-Xa assay
Not required  
routinely 
Anti-Xa assay
Not required  
routinely 
Anti-Xa assay
Not required routinely 
Anti-Xa assay
INR Not required routinely 
Diluted thrombin time
Not required routinely 
Anti-Xa assay
Not required routinely 
Anti-Xa assay
NA NA
Approval date 1939 (EU, US) 1985 (EU, dalteparin) 
1993 (US, enoxaparin)
Not yet approved 2000 (US) 
2002 (EU)
Not yet approved 1941 
(US, dicumarol) 
1953 (EU, phenprocoumon)
2008 (EU) 
2010 (US)
2008 (EU) 
2011 (US)
2011 (EU) 
2013 (US)
2011 (Japan) Not yet 
approved
Notes: †Ardeparin, bemiparin, certoparin, dalteparin, enoxaparin, nadroparin, parnaparin, reviparin, tinzaparin; ‡dicumarol (no longer available), warfarin, acenocoumarol, 
phenprocoumon; §inhibition of vitamin K epoxide reductase; ¶potential pharmacodynamic interactions with other drugs that alter haemostasis (eg, other anticoagulants, 
fibrinolytics, and antiplatelet drugs).
Abbreviations: ACT, activated coagulation time; aPTT, activated partial thromboplastin time; AT, antithrombin; inh/ind, inhibitors/inducers; CYP, cytochrome P450; 
EU, European Union; INR, international normalized ratio; IV, intravenous; LMwH, low molecular weight heparin; NA, data not available; PD, pharmacodynamics; P-gp, 
P-glycoprotein; PK, pharmacokinetics; SC, subcutaneous; Tmax, time to maximum concentration; US, United States; VKA, vitamin K antagonist.
therapy 6.4%; HR 0.39; 95% CI 0.14–1.11), with similar 
rates of bleeding events (OR 0.89; 95% CI 0.50–1.59) and 
death (HR 0.99; 95% CI 0.66–1.48).45
Acute and long-term treatment  
of pulmonary embolism
In patients with pulmonary embolism (van Gogh-PE trial, 
n = 2215), idraparinux was less effective than standard 
 therapy.44 The incidence of recurrence at day 92 was 3.4% in the 
idraparinux 2.5 mg once weekly group and 1.6% in the standard 
therapy group (OR 2.14; 95% CI 1.21–3.78). Clinically relevant 
bleeding rates at 6 months were similar (7.7% versus 9.7%) 
and death rates were higher with idraparinux than with standard 
therapy (6.4% versus 4.4%; P = 0.04). A total of 320 patients 
had a history of cancer. No subgroup analysis of patients with 
cancer is available from the van Gogh-PE study.
Extended treatment of VTE
During a 6-month extension of thromboprophylaxis (van 
 Gogh-Extension trial, n = 1215),46 idraparinux 2.5 mg once 
weekly was more effective than placebo in preventing recur-
rent VTE (1.0% versus 3.7%; OR 0.27; 95% CI 0.11–0.66; 
P = 0.002) but was associated with an excessive risk of major 
hemorrhage (1.9% versus 0%; P , 0.001), including three 
fatal intracranial bleeds. A total of 120 patients had a history 
of cancer, but no efficacy or safety data were reported for 
this subgroup.
Follow-up data from the van Gogh clinical trials sug-
gests that the very long elimination half-life of idraparinux 
may explain the increase in bleeding complications in the 
extension trial.47 Clinical development of idraparinux, which 
has no antidote, was halted in favor of idrabiotaparinux, for 
which an antidote (avidin) is readily available.
Idrabiotaparinux
Idrabiotaparinux (biotinylated idraparinux, SSR126517E, 
Sanofi-Aventis) is a long-acting synthetic pentasaccha-
ride with pharmacokinetic and anticoagulant properties 
similar to those of the previous compound, idraparinux 
(Table 2).40–42 Unlike idraparinux, the anticoagulant effect of 
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 idrabiotaparinux can be rapidly neutralized because of its 
binding to the biotin moiety following intravenous infusion of 
avidin (EP5001), an egg-derived protein.48 The main results 
of the studies using idrabiotaparinux in the treatment of VTE 
are summarized in Table 3 and are discussed below. No clini-
cal studies are currently ongoing with this compound.
Acute and long-term treatment  
of deep vein thrombosis
The EQUINOX study49 was a randomized double-blind trial 
comparing the efficacy and safety of idrabiotaparinux 3 mg 
and idraparinux 2.5 mg, each given subcutaneously once 
weekly for 6 months in patients with acute symptomatic deep 
vein thrombosis (Table 3). A total of 757 patients underwent 
randomization, of whom 5.2% (n = 39) had active cancer. No 
efficacy or safety data were reported in this  subpopulation. 
In the overall population, rates of recurrent VTE and 
of fatal or nonfatal pulmonary embolism were similar 
between idrabiotaparinux (2.3%, nine of 386 patients) and 
idraparinux (3.2%, 12 of 371 patients) at 6 months (absolute 
risk difference −0.9%; 95% CI −3.2 to 1.4). The study was 
not powered for efficacy, so no definitive conclusions can 
be made in this regard. There was less clinically relevant 
bleeding (5.2% versus 7.3%) and less major bleeding (0.8% 
versus 3.8%) with idrabiotaparinux than with idraparinux 
(Table 3). The finding of lower bleeding rates with idrabi-
otaparinux than with idraparinux is intriguing, given that 
both drugs exerted similar inhibition of FXa activity. This 
difference cannot be explained by the administration of 
avidin, because it occurred in only three patients during the 
6-month study period.
Long-term treatment of pulmonary 
embolism
CASSIOPEA50 was a randomized, double-blind, double-
dummy, noninferiority trial that compared the efficacy and 
safety of idrabiotaparinux versus warfarin in the long-term 
treatment of symptomatic pulmonary embolism. Patients 
were randomized to receive initial treatment for acute pulmo-
nary embolism of enoxaparin 1 mg/kg subcutaneously twice 
daily for 5–10 days, followed by idrabiotaparinux (starting 
dose 3 mg subcutaneously once weekly) or enoxaparin 
1 mg/kg subcutaneously twice daily or 5–10 days, overlap-
ping with and followed by dose-adjusted warfarin (INR 2-3). 
These regimens lasted 3 or 6 months depending on clinical 
presentation. A total of 3202 patients were enrolled, of whom 
5.9% (190 patients) had cancer present or treated in the 
last 6 months. No subgroup analysis for the cancer patients 
is available. Recurrent VTE at 99 days (main outcome) was 
similar in both treatment groups (2% versus 3%; OR 0.79; 
95% CI 0.50–1.25; prespecified noninferiority limit 2.0; non-
inferiority P = 0.0001). There were fewer clinically relevant 
bleeding episodes (main safety outcome) in patients in the 
enoxaparin-idrabiotaparinux group than in the enoxaparin-
warfarin group (5% versus 7%: OR 0.67; 95% CI 0.49–0.91; 
P = 0.0098). Differences in outcome were similar in patients 
treated to 6 months. In conclusion, idrabiotaparinux could 
provide an alternative to warfarin for the long-term treatment 
of pulmonary embolism, and seems to be associated with 
reduced bleeding.
Novel oral direct Factor Xa inhibitors
Rivaroxaban
Rivaroxaban (BAY 59-7939, Xarelto®, Bayer HealthCare) 
is an oxazolidinone derivative with a molecular weight of 
436 Da and high selectivity for direct inhibition of FXa 
(Table 2).51 In healthy subjects, rivaroxaban was well toler-
ated, with a predictable pharmacological profile for single 
and repeated doses.51,52 Maximum inhibition of FXa activity 
was 75% after a single oral dose of 40 mg.53 Peak plasma 
levels are reached in about 3 hours. Half-life ranges from a 
mean of 7 (5–9) hours in healthy volunteers to 12 (11–13) 
hours in elderly people. Rivaroxaban is metabolized in the 
liver by cytochrome P450 (CYP3)A4 and, to a lesser extent, 
via CYP2J2.54 Rivaroxaban is mainly excreted by the kidneys 
(Table 2) and to a lesser extent by the bile and intestines via 
the P-glycoprotein transport system. Caution must be exer-
cised in patients receiving treatment with potent inhibitors 
of both CYP3A4 and P-glycoprotein, such as ketoconazole 
or ritonavir.55
Rivaroxaban is currently approved in the European 
Union, the US, and other countries for VTE prophylaxis 
after total hip replacement or total knee arthroplasty on the 
basis of the RECORD1-4 studies,56–59 as well as for stroke 
prevention in atrial fibrillation based on the ROCKET-AF 
clinical trial.60 Rivaroxaban is also approved in several 
regions for the acute and long-term treatment of VTE as 
a result of the positive results obtained in the EINSTEIN 
studies.61,62 A pilot study (Catheter 2) is currently investigat-
ing rivaroxaban for the treatment of central line-associated 
blood clots in cancer patients (n = 72, ClinicalTrials.gov 
ID, NCT01708850).
The main results of the completed Phase III studies 
for nonsurgical VTE prophylaxis or treatment of VTE 
(Tables 4 and 5, respectively), are discussed below, paying 
special attention to data available for cancer patients.
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VTE prophylaxis in medical patients
The MAGELLAN study63–65 was a multinational, multicenter, 
randomized, double-blind controlled trial in which medical 
patients aged $ 40 years hospitalized for acute medical  illness 
with decreased level of mobility were randomized to oral 
rivaroxaban 10 mg once daily for 35 days or enoxaparin 40 mg 
for 10 days followed by placebo until completion of 35 days 
of treatment. A total of 8101 patients were randomized, of 
whom 584 (7%) had concomitant cancer. The primary efficacy 
outcome (composite of asymptomatic proximal deep vein 
thrombosis of the lower limbs detected by ultrasonography, 
proximal or distal symptomatic deep vein thrombosis, or symp-
tomatic pulmonary embolism) occurred in 2.7% of patients in 
each group (relative risk [RR] 0.97; 95% CI 0.71–1.33; RR 
noninferiority margin 1.5; noninferiority P value = 0.0025) on 
day 10, and in 4.4% of patients on rivaroxaban and in 5.7% of 
patients on enoxaparin followed by placebo (RR 0.77; 95% CI 
0.62–0.96; superiority P value 0.0211) on day 35.
Rivaroxaban demonstrated more clinically relevant bleed-
ing (main safety outcome) than enoxaparin on day 10 (2.8% 
versus 1.2%; RR 2.3; 95% CI 1.63–3.17; P , 0.0001) and day 
35 (4.1% versus 1.7%; RR 2.5; 95% CI 1.85–3.25; P , 0.0001). 
Major bleeding was also more frequent with rivaroxaban than 
with enoxaparin on day 10 (0.6% versus 0.3%; RR 2.2; 95% 
CI 1.07–4.45; P = 0.0318) and day 35 (1.1% versus 0.4%; RR 
2.9; 95% CI 1.60–5.15; P , 0.001). Death rates were similar 
in both groups by day 35 (5.1% versus 4.8%).
In subgroup analyses, extended thromboprophylaxis 
with rivaroxaban showed a nonsignificant trend towards 
less efficacy than short-term enoxaparin in patients with 
active cancer on day 35 (9.9% versus 7.4%; RR 1.34; 95% 
CI 0.71–2.54),64,65 while clinically relevant bleeding was more 
frequent with rivaroxaban than with enoxaparin plus placebo 
on day 35 (5.4% versus 1.7%,64 RR 3.16; 95% CI 1.17–8.50; 
authors’ calculation). In conclusion, rivaroxaban was nonin-
ferior to enoxaparin for short-term thromboprophylaxis and 
superior to enoxaparin plus placebo for extended thrombopro-
phylaxis. The efficacy of rivaroxaban was consistent across 
all covariates analyzed, with the exception of active cancer.65 
Bleeding rates were significantly increased with rivaroxaban 
in patients with cancer and in the overall study population.
Acute and long-term treatment  
of deep vein thrombosis  
and pulmonary embolism
The EINSTEIN-DVT study61 was an open-label, random-
ized, event-driven, noninferiority study that compared oral 
rivaroxaban alone (15 mg twice daily for 3 weeks, followed 
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by 20 mg once daily) subcutaneous enoxaparin followed by 
a vitamin K antagonist (either warfarin or acenocoumarol) 
for 3, 6, or 12 months in patients with acute, symptomatic 
deep vein thrombosis. The study included 3449 patients, 
of whom 207 (6%) had active cancer. Rivaroxaban had 
noninferior efficacy for the primary outcome of symp-
tomatic recurrent VTE (2.1% versus 3.0%; HR 0.68; 95% 
CI 0.44–1.04; noninferiority P value , 0.001). Clinically 
relevant bleeding (primary safety outcome) occurred 
in 8.1% of patients in each group (Table 5). In cancer 
patients, both groups had similar rates of recurrent VTE 
(3.4%  versus 5.6%) and clinically relevant bleeding (14.4% 
versus 15.9%).
The EINSTEIN-PE study62 was a randomized, open-label, 
event-driven, noninferiority trial involving 4832 patients 
who had acute symptomatic pulmonary embolism with 
or without deep vein thrombosis. The authors compared 
rivaroxaban (15 mg twice daily for 3 weeks, followed by 
20 mg once daily) with standard therapy of enoxaparin fol-
lowed by an adjusted-dose vitamin K antagonist for 3, 6, or 
12 months. A total of 4833 patients underwent randomization, 
of whom 223 (4.6%) had active cancer. Rivaroxaban was 
noninferior to standard therapy for the primary outcome of 
symptomatic recurrent VTE (2.1% versus 1.8%; HR 1.12; 
95% CI 0.75–1.68; noninferiority margin 2.0; P = 0.003). 
The primary safety outcome occurred at similar rates in the 
rivaroxaban and standard therapy groups (10.3% versus 
11.4%, respectively; HR 0.90; 95% CI 0.76–1.07; P = 0.23). 
Major bleeding rates with rivaroxaban were lower than 
with standard treatment (1.1% versus 2.2%; HR 0.49; 95% 
CI 0.31–0.79; P = 0.003). Deaths were numerically higher 
with rivaroxaban than with standard treatment (58 versus 50; 
P = 0.53). In cancer patients, both groups had similar rates 
of recurrent VTE (1.8% versus 2.8%) and clinically relevant 
bleeding (12.3% versus 9.3%).
The overall data from the EINSTEIN-DVT and 
 EINSTEIN-PE studies suggest that the single-drug approach 
to the initial and long-term treatment of deep vein thrombosis 
or pulmonary embolism with rivaroxaban is at least as effec-
tive and safe as standard treatment with enoxaparin and a 
vitamin K antagonist. We have conducted a pooled analysis 
of both studies comparing rivaroxaban and standard treatment 
in the subgroup of patients with cancer (Figure 2), based on 
subgroup data reported in the original publications.61,62 The 
pooled analysis suggests that the treatment groups had a 
similar risk of recurrent VTE (RR 0.62; 95% CI 0.22–1.74) 
and clinically relevant bleeding (RR 1.07; 95% CI 0.65–1.75) 
in cancer patients.
Extended treatment of deep vein 
thrombosis and pulmonary embolism
The EINSTEIN-extension study61 was a double-blind, 
randomized, event-driven, superiority study that compared 
rivaroxaban 20 mg once daily with placebo for an additional 
6 or 12 months in patients who had completed 6–12 months 
of treatment for VTE. The study included 1197 patients, 
of whom 54 (4.5%) had active cancer. Rivaroxaban had 
superior efficacy compared with placebo for the primary 
endpoint of symptomatic recurrent VTE (1.3% versus 7.1%; 
HR 0.18; 95% CI 0.09–0.39; P , 0.001). Major bleeding 
(the main safety outcome) occurred in four (0.7%) patients 
in the rivaroxaban group versus none in the placebo group 
(P = 0.11). Clinically relevant bleeding was more frequent 
with rivaroxaban than with placebo (6% versus 1.2%; HR 
5.19; 95% CI 2.3–11.7). Three patients died during the study 
(one in the rivaroxaban group and two in the placebo group). 
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Figure 2 Pooled analysis of recurrent venous thromboembolism and clinically relevant bleeding in patients with cancer included in the EINSTEIN-DVT and EINSTEIN-PE 
studies.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
219
Anticoagulants for venous thromboembolism in cancer patients
Vascular Health and Risk Management 2013:9
No subgroup analysis in cancer patients is available for this 
study.
Apixaban
Apixaban (BMS-562247-01, Eliquis®, Bristol-Myers Squibb) 
is an oral, direct, and highly selective FXa inhibitor. Apixaban 
was effective in the prevention of experimental thrombosis at 
doses that preserve hemostasis in rabbits.66 In humans, apixa-
ban is absorbed relatively rapidly, with peak concentrations 
achieved approximately 3 hours post-dosing, and a mean 
terminal half-life ranging from 8 to 15 hours.67 Apixaban is 
metabolized mainly via CYP3A4/5, with minor contributions 
from CYP1A2, 2C8, 2C9, 2C19, and 2J2.68 Apixaban is also a 
substrate of the transport proteins, P- glycoprotein and breast 
cancer resistance protein.68 Drug-drug interaction studies 
show a two-fold increase in exposure to apixaban after admin-
istration of potent inhibitors of CYP3A4 and P-glycoprotein 
(eg, ketoconazole), while the exposure to apixaban decreases 
by 50% after concomitant administration of potent inducers 
of CYP3A4 and P-glycoprotein (eg, rifampicin). Therefore, 
in these clinical situations, apixaban should be administered 
with caution.67 Apixaban has multiple routes of elimination. 
Renal excretion of apixaban accounts for approximately 27% 
of total clearance (Table 2).69
Apixaban is currently authorized in the European Union 
and other regions for VTE prophylaxis after total hip 
replacement or total knee arthroplasty on the basis of the 
ADVANCE1-3 studies,70–72 as well as for stroke prevention 
in atrial fibrillation based on the ARISTOTLE study.73 The 
main results of the completed Phase II–III studies for nonsur-
gical VTE prophylaxis or treatment of VTE (Tables 4 and 5, 
respectively) are discussed below, paying special attention 
to data available from cancer patients.
VTE prevention in medical patients  
on chemotherapy
ADVOCATE74 was a Phase II pilot study evaluating 
whether apixaban would be well tolerated and acceptable 
in cancer patients receiving chemotherapy. The study 
enrolled patients receiving either first-line or second-line 
chemotherapy for advanced or metastatic breast (n = 32), 
pancreatic (n = 15), gastrointestinal (n = 16), lung (n = 12), 
ovarian (n = 2), or prostate cancers (n = 13), myeloma/
lymphoma (n = 21), and cancers of unknown origin. Use 
of the study drug began within 4 weeks of the start of che-
motherapy. Patients at moderate to high risk of bleeding 
were excluded (eg, patients with prolonged coagulation 
times or receiving antiplatelet therapy, bevacizumab, or 
other therapies with potential to cause bleeding). A total 
of 125 patients were randomized to receive once-daily 
doses of apixaban 5 mg (n = 32), 10 mg (n = 30), 20 mg 
(n = 33), or placebo (n = 30) in a double-blind manner for 
12 weeks. In these groups, the number of clinically relevant 
bleeding episodes (main outcome) were one (3.1%), one 
(3.4%), four (12.5%), and one (3.4%). The corresponding 
number of major bleeding episodes was 0, 0, two, and one, 
respectively. There were no fatal bleeding episodes. No 
subjects in any of the apixaban groups and three patients 
in the placebo group (10.3%) developed symptomatic 
VTE. Three patients died (apixaban 5 mg, heart failure; 
placebo, heart failure and progressive cancer). There was a 
strong linear dose-response effect across the apixaban dose 
groups, with prothrombin fragments F1 and F2 decreasing 
by 1.9% (95% CI 0.7–3.1; P = 0.004) for each milligram of 
drug. In conclusion, apixaban 5 mg and 10 mg once daily 
were well tolerated in this study and associated with a low 
risk for VTE, thus supporting further study of apixaban in 
Phase III trials to prevent VTE in cancer patients receiving 
chemotherapy. These findings are limited due to the small 
sample size, the lack of screening for asymptomatic events, 
and the exclusion of patients at moderate to high bleeding 
risk. No further confirmatory studies are currently ongoing 
with apixaban in this setting.
VTE prophylaxis in medical patients
The ADOPT study75 was a double-blind, double-dummy, 
placebo-controlled trial in which acutely ill hospitalized 
medical patients were randomly assigned to receive apixaban 
orally at a dose of 2.5 mg twice daily for 30 days or subcuta-
neous enoxaparin at a dose of 40 mg once daily for 6–14 days. 
A total of 6528 subjects underwent randomization, of whom 
632 (9.7%) had a history of cancer (active or past). The 
primary efficacy outcome (major VTE or death on day 30) 
occurred at a similar rate in the apixaban extended-course 
and enoxaparin short-term course groups (2.71% versus 
3.06%; RR 0.87; 95% CI 0.62–1.23; P = 0.44). By day 30, 
major bleeding rates were low, but higher in the apixaban 
group than in the enoxaparin group (0.47% versus 0.19%; RR 
2.58; 95% CI 1.02–7.24; P = 0.04). In conclusion, in medi-
cally ill patients, an extended course of thromboprophylaxis 
using apixaban was not superior to a shorter course using 
enoxaparin and was associated with significantly more major 
bleeding events than was enoxaparin. No subgroup analyses 
in patients with cancer are currently available.
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Extended treatment of deep vein 
thrombosis and pulmonary embolism
The AMPLIFY-EXT study76 was a randomized, double-
blind trial that compared two doses of apixaban (2.5 mg 
and 5 mg twice daily) with placebo for one additional year 
in patients with VTE who had completed 6–12 months of 
anticoagulation therapy. A total of 2486 patients underwent 
randomization, of whom 2482 were included in the intention-
to-treat analyses. Of these, 42 (1.7%) had active cancer at 
baseline, but no efficacy or safety data have been reported 
in this subpopulation. Symptomatic recurrent VTE occurred 
less often in patients who were receiving apixaban 2.5 mg 
(1.7%) or 5 mg (1.7%) than in patients who were receiving 
placebo (8.8%, RR of apixaban 2.5 mg versus placebo 0.19, 
95% CI 0.11–0.33; RR of apixaban 5 mg versus placebo 0.20, 
95% CI 0.11–0.34). The rates of major bleeding (main safety 
outcome) were very low, and were similar in the three groups 
(0.2% versus 0.1% versus 0.5%, Table 5). The rates of clini-
cally relevant bleeding were 3.2%, 4.3%, and 2.7% (RR of 
apixaban 2.5 mg versus placebo 1.20, 95% CI 0.69–2.10; RR 
of apixaban 5 mg versus placebo 1.62, 95% CI 0.96–2.73). In 
conclusion, extended anticoagulation with apixaban reduced 
the risk of recurrent VTE without significantly increasing the 
rate of major or clinically relevant bleeding.
Acute and long-term treatment  
of deep vein thrombosis  
and pulmonary embolism
A pivotal Phase III trial is ongoing to assess a single-
drug approach with apixaban versus standard therapy for the 
acute and long-term treatment of VTE (AMPLIFY study, 
n = 4816 patients, www.clinicaltrials.gov ID, NCT00643201, 
Table 5).
Edoxaban
Edoxaban (DU-176b, Lixiana®, Daiichi-Sankyo), the free 
form of edoxaban tosilate hydrate, is a novel oral direct FXa 
inhibitor.77 In animal models, edoxaban inhibited venous 
thrombosis to an extent comparable with that of warfarin and 
enoxaparin, and the bleeding tendency was low.78 Edoxaban 
is rapidly absorbed following oral administration, with a 
time to peak plasma concentrations of 1–2 hours.79 Ter-
minal elimination half-life ranges from 5.8 to 10.7 hours. 
 Approximately 36%–45% of the dose administered is cleared 
through the kidneys (Table 2), and dose adjustment is needed 
in patients with renal impairment, low body weight, and/or 
older age.79,80 Edoxaban is mainly metabolized through hydro-
lysis, and CYP enzymes appear to have an insignificant role 
in its metabolism.81 P-glycoprotein inhibitors are expected 
to increase the bioavailability of edoxaban by inhibition of 
P-glycoprotein in the intestine, and a reduced dose should 
be considered.80
Edoxaban tosilate hydrate has been marketed in Japan 
since 2011 for the prevention of VTE in patients undergo-
ing major orthopedic surgery80 on the basis of the results 
of the pivotal STARS studies.82–85 The compound has also 
shown promising results in a Phase IIb study in patients 
with nonvalvular atrial fibrillation.86 A confirmatory study 
(ENGAGE AF-TIMI 48 study)87 is underway in this indica-
tion  (ClinicalTrials.gov ID, NCT00781391). An additional 
pivotal study is ongoing in the long-term treatment of deep 
vein thrombosis and pulmonary embolism (Edoxaban 
Hokusai-VTE study; n = 8250 patients, Table 5). However, 
one of the exclusion criteria is patients with active cancer 
for whom long-term treatment with LMWH is anticipated 
 (ClinicalTrials.gov ID, NCT00986154). The results are 
expected in 2013. No specific clinical studies in cancer 
patients are currently ongoing with edoxaban.
Betrixaban
Betrixaban (PRT-054021, Portola Pharmaceuticals, South 
San Francisco, CA) is an oral direct FXa inhibitor.88 
 Betrixaban has demonstrated antithrombotic activity in 
animal models of thrombosis, and inhibited generation of 
thrombin in human blood at concentrations that may prevent 
VTE in humans.89 Following oral administration, bioavail-
ability is 34% and the half-life is 19 hours, which allows 
once-daily dosing. Betrixaban is not a substrate for major 
CYP enzymes,90 but is a substrate for efflux proteins, includ-
ing P-glycoprotein (Table 2). The major biotransformation 
pathway for betrixaban is hydrolysis and, to a lesser extent, 
demethylation.90 It is excreted almost unchanged in bile 
(82%–89%) and urine (6%–13%).91
The compound has shown promising results in dose-
 finding studies for VTE prophylaxis in patients undergo-
ing total knee arthroplasty (EXPERT study)91 and for 
stroke prevention in atrial fibrillation (EXPLORE-Xa),92 
but it has not been developed further in these indica-
tions. The Phase III pivotal APEX study is evaluating 
extended-duration oral betrixaban 80 mg once daily (for 
28–42 days) with standard of care subcutaneous enoxaparin 
40 mg once daily (for 6–14 days) for hospital and post-
discharge prevention of VTE in acutely ill medical patients 
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(ClinicalTrials.gov ID, NCT01583218).  Concomitant 
cancer is not an exclusion criterion, and probably a sub-
set of patients recruited will have cancer, in line with 
 MAGELLAN63–65 and ADOPT.75 The global trial is expected 
to enroll approximately 6850 patients and is to be completed 
in December 2014 (Table 4). Portola is developing in parallel 
a universal antidote for Factor Xa inhibitor anticoagulants 
known as PRT064445, which is currently in Phase II in 144 
healthy volunteers (ClinicalTrials.gov ID, NCT01758432). 
No specific clinical studies in patients with cancer are cur-
rently ongoing with betrixaban.
Novel direct oral thrombin 
inhibitors
Dabigatran etexilate
Dabigatran etexilate (BIBR 1048, Pradaxa®, Boehringer 
Ingelheim) is a small molecule prodrug.93 After oral 
administration, dabigatran etexilate is rapidly absorbed and 
converted to its active metabolite, dabigatran (BIBR 953 
ZW), by esterase-catalyzed hydrolysis in plasma and in the 
liver. Dabigatran is a potent, competitive, direct thrombin 
 inhibitor. The absolute bioavailability of dabigatran follow-
ing oral administration of dabigatran etexilate is approxi-
mately 6.5% (Table 2).94 Maximum plasma concentrations 
are reached within 0.5 and 2 hours of oral administration,94 
but are delayed up to 6 hours if the oral dose is given early 
after surgery.95 It is eliminated primarily unchanged in the 
urine (85%, Table 2).96 Dabigatran exposure is increased 
approximately 2.7-fold to 6-fold in moderate to severe renal 
insufficiency, respectively.97 Dose adjustment is needed in 
moderate renal insufficiency, while it is contraindicated in 
severe renal insufficiency.97 Concomitant treatment with 
dabigatran and quinidine, a potent P-glycoprotein inhibi-
tor, is contraindicated, while caution should be exercised 
with other strong P-glycoprotein inhibitors like verapamil 
or clarithromycin. Potent P-glycoprotein inducers, such as 
rifampicin or St John’s wort (Hypericum perforatum), may 
reduce the systemic exposure of dabigatran.97
Dabigatran etexilate is currently marketed in several 
regions for VTE prophylaxis after total hip replacement 
or total knee arthroplasty on the basis of four major 
clinical trials (RE-NOVATE I and II, RE-MODEL, and 
 RE-MOBILIZE).98–101 It is also approved in several regions 
for stroke prevention in patients with atrial fibrillation 
based on the results of the RE-LY clinical trial.102 The main 
results of the studies in the treatment of VTE (Table 5), 
some of them including data in patients with cancer, are 
discussed below.
Long-term treatment of VTE
RE-COVER103 was a randomized, double-blind, noninferiority 
trial involving patients with acute VTE who were initially given 
parenteral anticoagulation therapy for a median of 9 days. The 
investigators compared oral dabigatran, administered at a dose 
of 150 mg twice daily, with warfarin dose-adjusted to achieve 
an INR of 2.0–3.0. The study randomized 2564 patients, of 
whom 2539 were included in the analysis (dabigatran, 1274; 
warfarin, 1265). Of these, 121 (4.8%) had active cancer at 
baseline. In total, 2.4% of patients (30/1274) on dabigatran 
and 2.1% (27/1265) on warfarin had recurrent symptomatic, 
objectively confirmed VTE and related deaths at 6 months 
(main study outcome, HR 1.10; 95% CI 0.65–1.84). Non-
fatal pulmonary embolism occurred in 13 patients assigned 
to dabigatran and in seven patients assigned to warfarin (HR 
1.85; 95% CI 0.74–4.64). Major bleeding rates were similar 
in the dabigatran and warfarin groups (1.6% versus 1.9%; 
HR 0.82; 95% CI 0.45–1.48), but episodes of any clinically 
relevant bleeding occurred less frequently with dabigatran 
than with warfarin (5.6% versus 8.8%; HR 0.63; 95% CI 
0.47–0.84). The relative risk of recurrent VTE with dabiga-
tran versus warfarin was similar among the 121 patients with 
cancer (RR 0.59; 95% CI 0.10–3.43) (Table 6). The relative 
risk of bleeding with dabigatran as compared with warfarin 
was similar among predefined subgroups,103 but the specific 
results in cancer patients have not been published.
The twin study, RECOVER II,104 included 2568 patients 
with acute VTE, and yielded very similar results to those 
of RECOVER (Table 5). No subgroup analysis is currently 
available. The authors concluded that dabigatran is nonin-
ferior to warfarin in the treatment of acute VTE and has a 
lower risk for bleeding.
Extended treatment of VTE
The RE-MEDY study105 compared extended treatment of 
VTE with dabigatran versus warfarin for a mean of 16 months 
in patients who had initially received 3–12 months of anti-
coagulant therapy. The study included 2856 patients, of 
whom 119 (4.2%) had active cancer. Dabigatran showed 
noninferior efficacy compared with warfarin with respect to 
recurrent VTE events (1.8% versus 1.3%; HR 1.44; 95% CI 
0.78–2.64; P = 0.03 for the prespecified noninferiority mar-
gin). There were fewer clinically relevant bleeding episodes 
but more acute coronary syndromes with dabigatran than 
with warfarin (Table 5). Death rates were similar in both 
groups. In cancer patients, recurrent VTE rates were 3.3% 
(two of 60) in the dabigatran group and 1.7% (one of 59) in 
the warfarin group.
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RE-SONATE105 investigated the extended treatment of 
VTE with dabigatran compared with placebo for 6 addi-
tional months in patients who had completed 6–18 months 
of anticoagulant therapy. Active cancer was an exclusion 
criterion. Dabigatran was superior to placebo in reducing the 
risk of recurrent VTE (0.4% versus 5.6%; HR 0.08; 95% CI 
0.02–0.25), but was associated with an increase in clinically 
relevant bleeding (5.3% versus 1.8%; HR 2.92; 95% CI 1.52–
5.60, Table 5). Rates of cardiovascular events and deaths were 
similar in both groups. The benefit in reduction of recurrent 
VTE was maintained at one-year post- treatment  follow-up 
(7.8% versus 11.6%; absolute risk difference −3.8%; 95% 
CI −7.1% to −0.5%; P = 0.0261).106
Discussion
Currently, the two major areas of investigation in VTE pro-
phylaxis and treatment of cancer patients are characteriza-
tion of ambulatory medical patients on chemotherapy (type 
and stage of cancer and type of chemotherapy) who would 
benefit most from prophylactic anticoagulation in terms of 
survival, thrombotic and bleeding events, and quality of life 
on the one hand, and establishment of the optimal duration 
of anticoagulation in patients with VTE and cancer.
With respect to the new parenteral indirect FXa inhibi-
tors, specific data in cancer patients are only available 
for semuloparin (Table 6). Data from the SAVE-ONCO 
study35–37 in cancer patients on chemotherapy are promising, 
but have been insufficient to gain regulatory approval. Key 
unanswered questions relate to the effect of anticoagulant 
treatment on quality of life and whether such treatment affects 
tumor growth or dissemination. Most important, additional 
evidence is required as to which patients with cancer (ie, the 
type and stage of cancer) would benefit most, what is the 
magnitude of the survival benefit, and if there is a benefit in 
cancers that respond poorly to other therapies.107
Once-weekly idrabiotaparinux dosing may potentially 
improve patient adherence in comparison with daily doses 
of a vitamin K antagonist.108 Subgroup analyses in patients 
with deep vein thrombosis suggest a similar effect of the 
related compound, idraparinux, in patients with or without 
cancer.45 However, its long half-life may be a drawback in 
cancer patients, who frequently undergo invasive diagnostic 
or therapeutic interventions that may require rapid reversal 
and rapid reintroduction of anticoagulation. The availability 
of an antidote (avidin) for idrabiotaparinux may help to 
alleviate worries about its long half-life.48
The data available with the new oral agents from specific 
studies in cancer patients are limited to a small dose-finding 
trial with apixaban for thromboprophylaxis in patients under-
going chemotherapy, and using placebo as the comparator 
(ADVOCATE study, Table 6).74 Other thromboprophylaxis 
studies with new oral anticoagulants in medical patients, 
not focused on cancer patients, show a similar efficacy or 
the new anticoagulant in comparison with LMWH during 
active treatment and increased bleeding risk.63,74 In subgroup 
analyses of the MAGELLAN study, rivaroxaban showed a 
nonsignificant trend towards less efficacy compared with 
enoxaparin in patients with active cancer (Table 6).65 The 
new oral anticoagulants may offer advantages over vitamin K 
antagonists in long-term and extended treatment of VTE, 
such as once-daily dosing and no need for routine monitor-
ing of its anticoagulant activity. A small pooled analysis of 
the cancer patients included in the EINSTEIN-DVT61 and 
EINSTEIN-PE62 studies suggests a similar efficacy and 
safety profile for rivaroxaban and warfarin in the long-term 
treatment of cancer patients with VTE (Figure 2). On the 
other hand, the new oral anticoagulants may eliminate the 
need for daily injection of LMWH in the treatment of VTE 
in cancer patients, but further specific studies are needed to 
demonstrate that the new agents are as effective and safe as 
the standard of care in cancer patients (LMWH).
There are pharmacodynamic differences between the old 
and new compounds, which may result in differential effects 
in cancer patients. The antithrombotic effect of LMWH is 
well established, and some of their pleiotropic effects, like 
inhibition of cell-cell interaction by blocking cell adhesion 
molecules (selectins), inhibition of extracellular matrix 
protease heparanase, and inhibition of angiogenesis,109 might 
translate into a survival benefit in patients with cancer.107 All 
these pleiotropic effects are unlikely to be shown with the 
synthetic and more selective new anticoagulants.110,111
The optimal duration of treatment with an anticoagulant 
after a first episode of VTE has not been studied in patients 
with cancer. According to current guidelines, patients with 
permanent risk factors for VTE, such as those with active 
cancer or receiving chemotherapy, may benefit from extended 
duration of anticoagulant therapy beyond 3–6 months 
(Table 1).15 Some studies with the new anticoagulants have 
assessed the issue of extending VTE treatment beyond 
3–6 months in comparison with warfarin105 or placebo,61,76,105 
but the percentage of patients with cancer included in these 
studies is very limited and further specific studies are needed.
With respect to safety, the lack of specific antidotes for 
the new oral anticoagulants may be problematic in patients 
with cancer, given that these patients are more likely to 
develop major bleeding complications during anticoagulant 
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treatment than those without malignancy.12 On the positive 
side, new oral anticoagulants may be potentially useful for 
anticoagulation in the management of patients with heparin-
induced thrombocytopenia, a rare but serious complication 
of heparin treatment,112 because they do not interact with 
PF4 in vitro,113,114 but further clinical studies are needed 
before recommendations can be made in this setting.
Conclusion
There are limited data available on the use of newer antico-
agulants in cancer patients. Whether novel anticoagulants 
have a role in cancer patients is currently unknown. Further 
specific data in cancer patients are needed before these agents 
could be recommended for prophylaxis or treatment of VTE 
in this special population.
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